OPGEN, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4437 USD | +0.38% |
|
-7.89% | +5.64% |
| Apr. 24 | OpGen Gets Notice of Noncompliance From Nasdaq | MT |
| Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2021 | 4.31M | Sales 2022 | 2.61M | Capitalization | 7.57M |
|---|---|---|---|---|---|
| Net income 2021 | -34M | Net income 2022 | -37M | EV / Sales 2021 | 6.51 x |
| Net cash position 2021 | 10.9M | Net Debt 2022 | 7.38M | EV / Sales 2022 | 5.74 x |
| P/E ratio 2021 |
-0.87
x | P/E ratio 2022 |
-0.18
x | Employees | 93 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 94.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on OpGen, Inc.
More recommendations
More press releases
| 1 day | +0.45% | ||
| 1 week | -10.09% | ||
| Current month | +9.68% | ||
| 1 month | -35.00% | ||
| 3 months | +5.04% | ||
| 6 months | -9.80% | ||
| Current year | +5.24% |
1 week
0.40
0.49
1 month
0.390.65
Current year
0.240.99
1 year
0.173.84
3 years
0.1774.40
5 years
0.17304.00
10 years
0.1754 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Albert Weber
DFI | Director of Finance/CFO | 60 | 21-12-31 |
Johannes Bacher
COO | Chief Operating Officer | 55 | 20-03-31 |
Oliver Schacht
PRN | Corporate Officer/Principal | 53 | 20-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Oliver Schacht
PRN | Corporate Officer/Principal | 53 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 0.4437 | +0.38% | 239 517 |
| 24-05-14 | 0.442 | +0.45% | 137,389 |
| 24-05-13 | 0.44 | -0.45% | 143,223 |
| 24-05-10 | 0.442 | -5.96% | 173,236 |
| 24-05-09 | 0.47 | -2.43% | 39,109 |
Delayed Quote Nasdaq, May 14, 2024 at 04:30 pm EDT
More quotes
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.24% | 5.58M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +46.73% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- OPGN Stock
